Annual Total Liabilities
$1.02 B
+$358.50 M+54.24%
31 December 2023
Summary:
Neurocrine Biosciences annual total liabilities is currently $1.02 billion, with the most recent change of +$358.50 million (+54.24%) on 31 December 2023. During the last 3 years, it has risen by +$320.90 million (+45.94%). NBIX annual total liabilities is now at all-time high.NBIX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$816.10 M
+$20.30 M+2.55%
30 September 2024
Summary:
Neurocrine Biosciences quarterly total liabilities is currently $816.10 million, with the most recent change of +$20.30 million (+2.55%) on 30 September 2024. Over the past year, it has dropped by -$203.30 million (-19.94%). NBIX quarterly total liabilities is now -24.87% below its all-time high of $1.09 billion, reached on 31 March 2024.NBIX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -19.9% |
| 3 y3 years | +45.9% | +16.8% |
| 5 y5 years | +52.4% | +22.0% |
NBIX Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +54.2% | -24.9% | +40.1% |
| 5 y | 5 years | at high | +67.5% | -24.9% | +40.1% |
| alltime | all time | at high | >+9999.0% | -24.9% | >+9999.0% |
Neurocrine Biosciences Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $816.10 M(+2.6%) |
| June 2024 | - | $795.80 M(-26.7%) |
| Mar 2024 | - | $1.09 B(+6.6%) |
| Dec 2023 | $1.02 B(+54.2%) | $1.02 B(+20.5%) |
| Sept 2023 | - | $846.10 M(+11.3%) |
| June 2023 | - | $760.10 M(+12.6%) |
| Mar 2023 | - | $675.30 M(+2.2%) |
| Dec 2022 | $660.90 M(-5.4%) | $660.90 M(+10.4%) |
| Sept 2022 | - | $598.80 M(+2.8%) |
| June 2022 | - | $582.30 M(-22.7%) |
| Mar 2022 | - | $753.40 M(+7.9%) |
| Dec 2021 | $698.50 M(+14.8%) | $698.50 M(+4.1%) |
| Sept 2021 | - | $671.30 M(-0.9%) |
| June 2021 | - | $677.20 M(+5.7%) |
| Mar 2021 | - | $640.80 M(+5.3%) |
| Dec 2020 | $608.50 M(-9.1%) | $608.50 M(-12.9%) |
| Sept 2020 | - | $698.30 M(+2.0%) |
| June 2020 | - | $684.40 M(+3.4%) |
| Mar 2020 | - | $661.60 M(-1.1%) |
| Dec 2019 | $669.10 M(+30.6%) | $669.10 M(+10.5%) |
| Sept 2019 | - | $605.42 M(+3.8%) |
| June 2019 | - | $583.15 M(+6.3%) |
| Mar 2019 | - | $548.45 M(+7.0%) |
| Dec 2018 | $512.39 M(+15.0%) | $512.39 M(+5.4%) |
| Sept 2018 | - | $486.23 M(+4.8%) |
| June 2018 | - | $463.88 M(+5.0%) |
| Mar 2018 | - | $441.87 M(-0.8%) |
| Dec 2017 | $445.45 M(+787.2%) | $445.45 M(+4.8%) |
| Sept 2017 | - | $424.98 M(+3.9%) |
| June 2017 | - | $408.85 M(+868.3%) |
| Mar 2017 | - | $42.22 M(-15.9%) |
| Dec 2016 | $50.21 M(-0.2%) | $50.21 M(+5.7%) |
| Sept 2016 | - | $47.51 M(-2.6%) |
| June 2016 | - | $48.80 M(+5.2%) |
| Mar 2016 | - | $46.37 M(-7.9%) |
| Dec 2015 | $50.33 M(+46.6%) | $50.33 M(+10.6%) |
| Sept 2015 | - | $45.49 M(+2.8%) |
| June 2015 | - | $44.27 M(+2.8%) |
| Mar 2015 | - | $43.05 M(+25.4%) |
| Dec 2014 | $34.33 M(+0.2%) | $34.33 M(+1.8%) |
| Sept 2014 | - | $33.71 M(+3.1%) |
| June 2014 | - | $32.69 M(+1.4%) |
| Mar 2014 | - | $32.24 M(-5.9%) |
| Dec 2013 | $34.27 M(-17.6%) | $34.27 M(-6.6%) |
| Sept 2013 | - | $36.67 M(-5.5%) |
| June 2013 | - | $38.80 M(-0.4%) |
| Mar 2013 | - | $38.97 M(-6.3%) |
| Dec 2012 | $41.61 M(-46.9%) | $41.61 M(-16.7%) |
| Sept 2012 | - | $49.95 M(-12.9%) |
| June 2012 | - | $57.35 M(-13.5%) |
| Mar 2012 | - | $66.31 M(-15.3%) |
| Dec 2011 | $78.29 M(-37.4%) | $78.29 M(-14.2%) |
| Sept 2011 | - | $91.28 M(-10.4%) |
| June 2011 | - | $101.85 M(-8.2%) |
| Mar 2011 | - | $111.00 M(-11.3%) |
| Dec 2010 | $125.08 M | $125.08 M(-6.2%) |
| Sept 2010 | - | $133.29 M(-6.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2010 | - | $142.63 M(+125.8%) |
| Mar 2010 | - | $63.16 M(-5.5%) |
| Dec 2009 | $66.86 M(-17.9%) | $66.86 M(-10.6%) |
| Sept 2009 | - | $74.83 M(-5.9%) |
| June 2009 | - | $79.52 M(-2.9%) |
| Mar 2009 | - | $81.92 M(+0.6%) |
| Dec 2008 | $81.41 M(-48.5%) | $81.41 M(-43.5%) |
| Sept 2008 | - | $144.09 M(-1.2%) |
| June 2008 | - | $145.83 M(+0.4%) |
| Mar 2008 | - | $145.22 M(-8.1%) |
| Dec 2007 | $157.96 M(+110.7%) | $157.96 M(+117.7%) |
| Sept 2007 | - | $72.54 M(-0.4%) |
| June 2007 | - | $72.81 M(+1.1%) |
| Mar 2007 | - | $72.01 M(-3.9%) |
| Dec 2006 | $74.96 M(-19.4%) | $74.96 M(-3.5%) |
| Sept 2006 | - | $77.66 M(-3.9%) |
| June 2006 | - | $80.77 M(-13.7%) |
| Mar 2006 | - | $93.57 M(+0.6%) |
| Dec 2005 | $93.02 M(-25.8%) | $93.02 M(-4.3%) |
| Sept 2005 | - | $97.23 M(-6.1%) |
| June 2005 | - | $103.49 M(-7.3%) |
| Mar 2005 | - | $111.65 M(-11.0%) |
| Dec 2004 | $125.39 M(-23.5%) | $125.39 M(-10.5%) |
| Sept 2004 | - | $140.06 M(+3.8%) |
| June 2004 | - | $134.94 M(-11.1%) |
| Mar 2004 | - | $151.86 M(-7.3%) |
| Dec 2003 | $163.84 M(+287.5%) | $163.84 M(-1.0%) |
| Sept 2003 | - | $165.57 M(+1.7%) |
| June 2003 | - | $162.79 M(+10.1%) |
| Mar 2003 | - | $147.83 M(+249.6%) |
| Dec 2002 | $42.28 M(+17.6%) | $42.28 M(+8.9%) |
| Sept 2002 | - | $38.81 M(+13.7%) |
| June 2002 | - | $34.14 M(-0.6%) |
| Mar 2002 | - | $34.35 M(-4.5%) |
| Dec 2001 | $35.96 M(+58.0%) | $35.96 M(+10.9%) |
| Sept 2001 | - | $32.42 M(+56.2%) |
| June 2001 | - | $20.76 M(+6.2%) |
| Mar 2001 | - | $19.55 M(-14.1%) |
| Dec 2000 | $22.75 M(+77.8%) | $22.75 M(+53.5%) |
| Sept 2000 | - | $14.82 M(+34.1%) |
| June 2000 | - | $11.05 M(-23.0%) |
| Mar 2000 | - | $14.36 M(+12.2%) |
| Dec 1999 | $12.80 M(+50.6%) | $12.80 M(+42.2%) |
| Sept 1999 | - | $9.00 M(+23.3%) |
| June 1999 | - | $7.30 M(+10.6%) |
| Mar 1999 | - | $6.60 M(-22.4%) |
| Dec 1998 | $8.50 M(-2.3%) | $8.50 M(+3.7%) |
| Sept 1998 | - | $8.20 M(+60.8%) |
| June 1998 | - | $5.10 M(-16.4%) |
| Mar 1998 | - | $6.10 M(-29.9%) |
| Dec 1997 | $8.70 M(+67.3%) | $8.70 M(+35.9%) |
| Sept 1997 | - | $6.40 M(-3.0%) |
| June 1997 | - | $6.60 M(+15.8%) |
| Mar 1997 | - | $5.70 M(+9.6%) |
| Dec 1996 | $5.20 M | $5.20 M(+30.0%) |
| Sept 1996 | - | $4.00 M(-18.4%) |
| June 1996 | - | $4.90 M(+25.6%) |
| Mar 1996 | - | $3.90 M |
FAQ
- What is Neurocrine Biosciences annual total liabilities?
- What is the all time high annual total liabilities for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly total liabilities year-on-year change?
What is Neurocrine Biosciences annual total liabilities?
The current annual total liabilities of NBIX is $1.02 B
What is the all time high annual total liabilities for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual total liabilities is $1.02 B
What is Neurocrine Biosciences quarterly total liabilities?
The current quarterly total liabilities of NBIX is $816.10 M
What is the all time high quarterly total liabilities for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly total liabilities is $1.09 B
What is Neurocrine Biosciences quarterly total liabilities year-on-year change?
Over the past year, NBIX quarterly total liabilities has changed by -$203.30 M (-19.94%)